We are dedicated to bringing transformative therapies to patients – empowering them to embrace life to its fullest.
Born out of the lab of Professor Patrick Gunning at the University of Toronto, a serial entrepreneur with a successful track record that includes Dunad, Dalriada Drug Discovery, and Janpix, HDAX Therapeutics was created with a foundation in translational science and a mission to advance revolutionary treatments.
Our entrepreneurial drug developers built the technology behind HDAX from a mere concept to distinct programs with therapeutical potential in neurology and cardiac diseases among others. With the support of world-class advisors and global accelerators, HDAX is well equipped with an extensive network, profound passion and unwavering tenacity to transform therapeutic outcomes for patients.
HDAX exists to deliver meaningful medicines for patients.
We recognize the challenges with current HDAC6 targeting strategies, and are fundamentally reconceptualizing the way it is approached to unlock its full therapeutic potential and revolutionize patient outcomes.
Our values serve as our inspiration to excel in our endeavours and never lose sight of why our work matters – to change patients’ lives.
HDAX has a unique blend of experienced leaders and passionate founders equipped with scientific background and business expertise to lead the future of precision HDAC6 targeting for diseases with high unmet needs.